Natures Sunshine Products Inc (NATR) stock
NATRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3058% below fair value
$10.33−0.23 (-2.18%)
Close on Nov 17, 2026Market cap $181.76MP/E 10.2Yield –
Natures Sunshine Products r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $1.90M, up 11.8% from the year before. Over ten years it grew -3.8% a year on average. The highest annual figure on record is $3.40M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.90M | +11.8% |
| FY2024 | Dec 31, 2024 | $1.70M | +6.3% |
| FY2023 | Dec 31, 2023 | $1.60M | +6.7% |
| FY2022 | Dec 31, 2022 | $1.50M | +7.1% |
| FY2021 | Dec 31, 2021 | $1.40M | -6.7% |
| FY2020 | Dec 31, 2020 | $1.50M | -28.6% |
| FY2019 | Dec 31, 2019 | $2.10M | -25.0% |
| FY2018 | Dec 31, 2018 | $2.80M | -17.6% |
| FY2017 | Dec 31, 2017 | $3.40M | +6.3% |
| FY2016 | Dec 31, 2016 | $3.20M | +14.3% |
| FY2015 | Dec 31, 2015 | $2.80M | +12.0% |
| FY2014 | Dec 31, 2014 | $2.50M | +25.0% |
| FY2013 | Dec 31, 2013 | $2.00M | +36.6% |
| FY2012 | Dec 31, 2012 | $1.46M | -5.7% |
| FY2011 | Dec 31, 2011 | $1.55M | -23.2% |
| FY2010 | Dec 31, 2010 | $2.02M | – |
See a number that looks wrong?